No Data
No Data
Express News | NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
Express News | NKGen Biotech - Snk02 Was Safe and Treatment Appeared to Stop Progression of Several Heavily Pretreated Solid Tumors as a Monotherapy
Express News | NKGen Biotech - Snk02 Appears to Have Some Clinical Activity Against Pretreated Solid Tumors Despite Lack of Lymphodepletion
Express News | NKGen Biotech Inc - Snk02 Was Found to Be Well Tolerated as a Monotherapy
Express News | NKGen Biotech To Present Updated Phase 1 Data Of SNK02 Allogeneic NK Cell Therapy In Solid Tumors At 6th Annual Allogeneic Cell Therapies Summit 2024
Express News | NKGen Biotech to Present Updated Phase 1 Data on Snk02 Allogeneic Nk Cell Therapy in Solid Tumors at the 6TH Annual Allogeneic Cell Therapies Summit 2024
No Data